Kite Pharma (KITE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results
March 26, 2015 8:01 AM EDTSANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported full-year and fourth quarter 2014 financial results for the period ended December 31, 2014.
"2014 was a transformative year for Kite, marked by achieving several key corporate and clinical milestones," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "In addition to our successful IPO and follow-on offering, we expanded our management team with world-class talent, filed our first... More
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
March 25, 2015 9:00 PM EDTSANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of... More
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
March 25, 2015 9:00 PM EDTSANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of... More
